CareDx Inc (NASDAQ:CDNA) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.
- Updated: October 16, 2016
Zacks Investment Research has upgraded CareDx Inc (NASDAQ:CDNA) to Hold in a statement released on 10/11/2016.
Having a price of $3.74, CareDx Inc (NASDAQ:CDNA) traded -2.63% lower on the day. With the last stock price down -18.87% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. CDNA has recorded a 50-day average of $4.13 and a two hundred day average of $4.56. Trade Volume was down over the average, with 19,595 shares of CDNA changing hands under the typical 25,065
Recent Performance Chart
CareDx Inc has with a one year low of $3.28 and a one year high of $6.87 and has a market capitalization of $0.
General Company Details For CareDx Inc (NASDAQ:CDNA)
CareDx, Inc. is a molecular diagnostics company. The Company is focused on the discovery, development and commercialization of clinically differentiated diagnostic surveillance solutions for transplant patients. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), is a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function having a low probability of moderate/severe acute cellular rejection. Its products under development for transplant monitoring include AlloSure, a development-stage transplant surveillance solution, which applies next generation sequencing to detect and quantitate genetic differences between donor-derived cell-free deoxyribonucleic acid (dd-cfDNA) in the blood stream emanating from the donor heart. It offers the AlloMap Score Variability service, which provides complementary information to help personalize long-term care of heart transplant recipients.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.